跳至主要内容
临床试验/EUCTR2017-002155-28-FR
EUCTR2017-002155-28-FR进行中(未招募)1 期

Evaluation of allopurinol treatment for autistic disorders and epilepsy in adenylosuccinate lyase deficiency (ADSL) - ADS

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)0 个研究点目标入组 8 人开始时间: 2018年6月7日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
8

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • -child (minimum age 18 months) or adult with adenylosuccinate lyase (ADSL) deficiency confirmed by quantification of SAICAr and urinary S-adenosine,
  • -consent of the patient, parents or legal representative,
  • -Beneficiary of social security coverage (affiliated or entitled).
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 2
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 6
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • -refusal by the child, his parents or his representative,
  • -known allergy to allopurinol or to one of the constituents of the product (notably lactose),
  • -Patients treated with Antipurines (azathioprine, mercaptopurine).
  • -renal insufficiency characterized by creatine clearance < 80 mL/min/1.73m²,
  • -breastfeeding,
  • -pregnancy.

研究者

相似试验